Yue Zhou

Yue Zhou

Auto-generated profile, based on publicly available information

Yue Zhou

Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
YZYue Zhou
Yue Zhou
RORyota Oki
Ryota Oki
ATAkihiro Tanaka
Akihiro Tanaka
LSLeixin Song
Leixin Song
ATAtsushi Takashima
Atsushi Takashima
HSHiroaki Sakurai
Hiroaki Sakurai
The receptor tyrosine kinase ephrin type-A receptor 2 (EphA2) is overexpressed in malignant tumors. We previously reported that non-canonical EphA2 phosphorylation at Ser-897 was catalyzed by p90 ribosomal S6 kinase (RSK) via the MEK-ERK pathway in ligand- and tyrosine kinase-independent manners. Non-canonical EphA2 activation plays a key role in tumor progression; however, its activation mechanism remains unclear. In the present study, we focused on cellular stress signaling as a novel inducer of non-canonical EphA2 activation. p38, instead of ERK in the case of epidermal growth factor signaling, activated RSK-EphA2 under cellular stress conditions, including anisomycin, cisplatin, and high osmotic stress. Notably, p38 activated the RSK-EphA2 axis via downstream MAPK-activated protein kinase 2 (MK2). Furthermore, MK2 directly phosphorylated both RSK1 Ser-380 and RSK2 Ser-386, critical residues for the activation of their N-terminal kinases, which is consistent with the result showing that the C-terminal kinase domain of RSK1 was dispensable for MK2-mediated EphA2 phosphorylation. Moreover, the p38-MK2-RSK-EphA2 axis promoted glioblastoma cell migration induced by temozolomide, a chemotherapeutic agent for the treatment of glioblastoma patients. Collectively, the present results reveal a novel molecular mechanism for non-canonical EphA2 activation under stress conditions in the tumor microenvironment.

1 December 2018 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
HIHirofumi Iitsuka
Hirofumi Iitsuka
KKKeiichi Koizumi
Keiichi Koizumi
AIAkiko Inujima
Akiko Inujima
MSMikiko Suzaki
Mikiko Suzaki
YMYusuke Mizuno
Yusuke Mizuno
NSNaotoshi Shibahara
Naotoshi Shibahara
Herbal medicine is mainly prepared from boiling herbal water extracts. Many epoch-making immunosuppressant drugs, such as glycyrrhizic acid (old example) and FTY720 (current example), were developed from herbal secondary metabolites in the boiling water extract by partition with organic solvents. However, few immunostimulants have been discovered by this method. Instead of the usual method, we aimed to find a novel immunostimulant component by two unique methods in the research of herbal medicine: ultracentrifugation and electron microscopy. The immunostimulant was not a secondary metabolite, as expected, but the structure was a nanoparticle formed by a polysaccharide. In addition, we clarified the immune effect of the nanoparticle. Intake of the nanoparticle by phagocytosis resulted in immunostimulant effects by increasing the genes and proteins of inflammatory cytokines in macrophage cells. The immunostimulant effects were inhibited by a phagocytosis inhibitor, cytochalasin D. To the best of our knowledge, this study is the first to describe the discovery of a nanoparticle in boiling herbal water extracts and its immunostimulant properties. This study will provide additional understanding of the efficacy of herbal medicine, in that the immunostimulant nanoparticle universally exists in boiling herbal water extracts. Thus, traditional herbal medicine may be an oldest known nanomedicine. Furthermore, this study suggests that the immunostimulant nanoparticle simply can be obtained from herbal medicine only by ultracentrifugation. We hope that this simple strategy will substantially contribute to drug development, including vaccine adjuvant, in the future.

11 June 2026 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
SSSo-ichiro Sasaki
So-ichiro Sasaki
RWRahajeng Fitria Wahyuniputri
Rahajeng Fitria Wahyuniputri
YTYamato Tanabe
Yamato Tanabe
YZYue Zhou
Yue Zhou
YTYuya Terashima
Yuya Terashima
YHYoshihiro Hayakawa
Yoshihiro Hayakawa
Bone metastasis is a critical factor in the morbidity and mortality of breast cancer patients, yet the specific contributions of the bone marrow microenvironment to this process remain incompletely understood. We investigated the influence of bone marrow cell populations on intraosseous tumor growth following the injection of E0771 breast cancer cells into the bone. Kinetic analysis revealed a progressive reduction in CD19+CD20+B220+ immature B cells as the tumor burden increased. Depletion of CD20+ immature B cells, but not CD19+CD20-B220+ pro/pre-B cells, significantly increased the intraosseous tumor burden along with upregulation of the proliferation marker Ki-67. To simulate the bone cavity environment, we employed anchorage-independent in vitro co-cultures of tumor cells with B-cell populations. Using this co-culture system, pro/pre-B cells, but not immature B cells, enhanced tumor cell proliferation with upregulation of Ki-67. Mechanistically, pro/pre-B cells enhanced tumor cell proliferation through the production of soluble factors and promoted stem cell-like properties, as indicated by increased expression of the stem cell marker CD44. By analyzing clinical datasets from breast cancer patients, we found that high CD20 expression correlated with longer overall survival, thereby supporting a positive correlation between increased immature B cells and better control of disease progression. Collectively, these results indicate contradictory roles for CD20- pro/pre-B cells and CD20+ immature B cells in controlling the tumor microenvironment in bone.

10 May 2023 in Organic & Biomolecular Chemistry
Verified
Journal Article
Open access
PDF file
AKAki Kohyama
Aki Kohyama
ASAya Shiuchi
Aya Shiuchi
YZYue Zhou
Yue Zhou
MTMasaru Tanioka
Masaru Tanioka
KSKenji Sugimoto
Kenji Sugimoto
YMYuji Matsuya
Yuji Matsuya
We screened α-methylene cyclopentanones (MCPs) for NF-κB pathway inhibitory activity. The conformation of biologically active diastereomers was controllable by the stereochemistry of the side chain.

19 September 2026 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JCJunya Chiba
Junya Chiba
TYTetsuya Yasukagawa
Tetsuya Yasukagawa
SYSatoru Yokoyama
Satoru Yokoyama
YZYue Zhou
Yue Zhou
YOYuki Ohishi
Yuki Ohishi
MIMasahiko Inouye
Masahiko Inouye

24 January 2026 in Journal of Biological Chemistry
Verified
Journal Article
Open access
IOIimi Onuma
Iimi Onuma
YIYusuke Iwata
Yusuke Iwata
YZYue Zhou
Yue Zhou
MNMai Nakada
Mai Nakada
AKArisa Kondo
Arisa Kondo
HSHiroaki Sakurai
Hiroaki Sakurai
Src is a non-receptor tyrosine kinase that is overexpressed and highly activated in many cancers and is one of the key factors contributing to malignant transformation. According to current concepts, Src activity relies on tyrosine phosphorylation, and phospho(p) Y419 in the activation loop is often regarded as a marker of its activation. However, recent studies have shown that pY419 may contribute to substrate selection. Therefore, the mechanisms underlying Src activation other than classical tyrosine phosphorylation warrant further study. We herein demonstrated that Src phosphorylates a novel substrate, TAB1, directly at Y481 in the TAK1-binding domain, changing the TAK1-TAB1 interaction. p38 enhances Src-mediated TAB1 phosphorylation through the direct phosphorylation of Src at N-terminal S75. Moreover, the mode of substrate recognition by the SH2 domain of Src is different in TAB1 than in FAK, a known SH2-dependent substrate. The present results identify a novel non-canonical Src activation mechanism based on serine phosphorylation and suggest pY481-TAB1 and pS75-Src as improved markers of Src activation, thereby offering alternative modes for assessing the Src activation status of Src-dependent cancers before and during targeted therapy.